Recommended by guidelines. Refused by public drug plans.
Public drug coverage for off-label Long COVID treatments
Canada invested $9 million in the Canadian Guidelines for Post-COVID-19 Condition (CAN-PCC). Yet when doctors prescribe the medications those guidelines recommend, provincial drug plans refuse to pay.
In Ontario, the public drug plan, which also covers people on ODSP and in the Trillium Drug Program, won’t pay for three of the five drugs CAN-PCC suggests for post-COVID POTS (ivabradine, carvedilol and midodrine) when they’re prescribed off-label. The Exceptional Access Program won’t consider a request unless the Executive Officer has already approved that use.
Patients shouldn’t be denied medically necessary treatment, or pay about $56 to $102 a month out of pocket, simply because an older medication is prescribed off-label.
- Our ask
- Cover off-label drugs that Long COVID guidelines recommend, starting with POTS drugs in Ontario.
- Who can act
- Ontario Ministry of Health · CDA-AMC
- Where it stands
- Submitting LCAC’s formal request to Ontario and gathering coverage reports from patients and clinicians.
- Next step
- Send the formal request to Ontario, collect letters, and check other provinces’ drug plans.
Why this matters: a coverage catch-22
Health Canada approves a drug for particular conditions. Prescribing it for something else is off-label. That’s normal and legal, and it’s how Canada’s Long COVID guidelines suggest several drugs be used. But guidelines and public drug plans are separate systems. Plans decide coverage on their own criteria, weighing cost and how certain the evidence is, and these recommendations are conditional and based on low certainty evidence. In Ontario, a funding review is usually started by the drug’s manufacturer.
Take post-COVID POTS in Ontario. Health Canada approved these drugs for other conditions, so prescribing them for POTS is off-label. Ontario’s drug plan only pays for ivabradine (Limited Use 538), carvedilol (Limited Use 183) and midodrine (Limited Use 1) when the prescription meets criteria written for heart failure or neurogenic orthostatic hypotension. Post-COVID POTS and inappropriate sinus tachycardia (IST) don’t qualify.
That’s the catch-22. These are older or generic drugs, so no manufacturer has a reason to ask Ontario to fund them for Long COVID. Without that request, the criteria never change.
There’s no appeal that works. The Exceptional Access Program, Ontario’s route for special requests, has a firm limit: “EAP requests are only considered for a drug or indication which has been approved for funding by the Executive Officer.” POTS isn’t one of those uses.
So patients pay out of pocket or go without. Ivabradine costs about $56 to $102 a month at Ontario’s list price, before pharmacy markup and dispensing fees. For people living on disability support or a reduced income, that’s out of reach.
For many patients, these drugs help considerably. Going without means more days unable to stand, work or look after yourself, for want of a prescription you can’t afford to fill.
About Canada’s Long COVID guidelines
The Canadian Guidelines for Post-COVID-19 Condition (CAN-PCC) are Canada’s first national clinical guidelines for Long COVID. McMaster University led the work with the CAN-PCC Collaborative, supported by a $9 million contribution from the Public Health Agency of Canada (McMaster announcement). The recommendations are free to read online.
Most CAN-PCC drug recommendations are conditional and based on low or very low certainty evidence. That means the panel thinks the option is reasonable for many patients, but the research is still limited. It doesn’t mean the drug doesn’t work.
What we’re asking Ontario
Ontario’s drug plan decisions are made by the Executive Officer of Ontario Public Drug Programs, advised by the Committee to Evaluate Drugs. We’re asking the Executive Officer to:
1. Refer ivabradine for review
Refer ivabradine to the Committee to Evaluate Drugs for adults with documented post-COVID POTS or IST when a covered beta-blocker, such as metoprolol, isn’t suitable or tolerated. That matches Germany’s public coverage decision, in effect since June 2026.
2. Review carvedilol and midodrine criteria
Review the Limited Use criteria for carvedilol (LU 183) and midodrine (LU 1) so documented post-COVID POTS can qualify. Today Ontario funds carvedilol only for heart failure and midodrine only for neurogenic orthostatic hypotension.
3. Ask for a national review
Join other provinces in asking Canada’s Drug Agency (CDA-AMC) for a Non-Sponsored Reimbursement Review, so provinces can evaluate off-label Long COVID treatments without waiting for a manufacturer to apply.
4. Open a route for input
Publish a clear way for patients and clinicians to give evidence through Ontario’s Patient Input Submissions process.
A drug company usually asks for a funding review, and ivabradine’s Canadian approval is for heart failure, not POTS. Provincial drug plans don’t have to wait: they can refer a question to the Committee to Evaluate Drugs, and jointly ask Canada’s Drug Agency for a non-sponsored review of an off-label use.
Metoprolol and pyridostigmine are already General Benefits. Antivirals for a new COVID-19 infection are a separate access question, so they’re listed below for reference.
Starting with Ontario
Each province and territory runs its own drug plan. We’re starting with Ontario because LCAC is based there and its formulary is public and searchable. Next, we’ll check what other provincial and territorial plans cover, and widen the campaign wherever the same gap exists. The same question applies to any guideline-recommended off-label treatment, so we’ll widen the campaign beyond POTS where we find the same gap.
Live outside Ontario? If one of these drugs was covered or refused for you, report coverage in your province, or ask your health minister to check your plan against CAN-PCC.
How Ontario’s public drug plans work
Ontario Drug Benefit (ODB)
The Ontario Drug Benefit program pays for most prescription drugs on the Ontario Drug Benefit Formulary for people who qualify:
- people 65 and older
- people 24 and younger who aren’t covered by a private plan (OHIP+)
- people receiving Ontario Works or Ontario Disability Support Program (ODSP) support
- people living in a long-term care home or a Community Home for Opportunity
- people receiving professional home and community care services
- people enrolled in the Trillium Drug Program
Seniors pay the first $100 of prescription costs each program year (1 August to 31 July), then up to $6.11 per prescription. Lower-income seniors can apply to the Seniors Co-Payment Program: no deductible and up to $2 per prescription.
Trillium Drug Program
The Trillium Drug Program is for people who don’t qualify for ODB, whose insurance doesn’t pay for all their drugs, and who spend about 4% or more of their after-tax household income on prescriptions. The household pays a yearly deductible, usually about 4% of after-tax income, in four quarterly amounts, then up to $2 per prescription.
Trillium covers the same drugs as ODB, under the same rules. It pays for drugs on the ODB Formulary and for Exceptional Access Program approvals. So if ODB won’t pay for an off-label use, Trillium won’t either.
General Benefit, Limited Use and the Exceptional Access Program
- General Benefit: covered for any use.
- Limited Use: covered only when the prescription meets Ontario’s published criteria. The prescriber writes the Limited Use code on the prescription.
- Exceptional Access Program (EAP): a doctor or nurse practitioner can ask for case-by-case funding. But “EAP requests are only considered for a drug or indication which has been approved for funding by the Executive Officer.” EAP also doesn’t fund natural health products.
How a drug use gets added
Usually the manufacturer asks for public funding. The drug is reviewed nationally by Canada’s Drug Agency (CDA-AMC), or in some cases by Ontario’s Committee to Evaluate Drugs. Provinces negotiate the price together through the pan-Canadian Pharmaceutical Alliance. Ontario’s Executive Officer makes the final decision (Ontario’s drug funding process). No manufacturer is asking for Long COVID uses to be funded, which is why patients and clinicians have to raise it.
What the guideline suggests and what Ontario covers
All of these are CAN-PCC conditional recommendations based on low or very low certainty evidence. A General Benefit is covered for any use. A Limited Use drug is covered only when the prescription meets Ontario’s published criteria. Ontario Drug Benefit status was checked on 7 November 2026 for the products named.
1. Long COVID with POTS or inappropriate sinus tachycardia
From the CAN-PCC recommendation published 1 November 2024. The panel assessed each drug on its own and had no evidence on combinations.
| Drug | What it does | Ontario Drug Benefit status |
| Ivabradine (Lancora) | Slows a fast heart rate. | Limited Use 538 Heart failure with reduced ejection fraction only. POTS and IST don’t qualify. |
| Carvedilol | Beta-blocker. Lowers heart rate and blood pressure. | Limited Use 183 Congestive heart failure only. POTS and IST don’t qualify. |
| Metoprolol | Beta-blocker. Slows a fast heart rate. | General Benefit Generic metoprolol tartrate tablets. |
| Pyridostigmine (Mestinon and generics) | May help symptoms on standing. An option when low blood pressure is the main problem. | General Benefit 60 mg tablets. |
| Midodrine | Raises blood pressure to help with dizziness on standing. | Limited Use 1 Disabling neurogenic orthostatic hypotension when other treatments, including fludrocortisone, haven’t worked or aren’t tolerated. POTS alone doesn’t qualify. |
2. Other options CAN-PCC suggests
The first four are for a new COVID-19 infection in someone who has Long COVID. CAN-PCC suggests not using the antivirals to treat Long COVID itself.
| Drug or product | What it does | Ontario Drug Benefit status |
| Metformin | Diabetes medicine. Suggested as a short course during a new COVID-19 infection. CAN-PCC ranks it ahead of Paxlovid for people with Long COVID. | General Benefit Immediate-release 500 mg tablets. |
| Nirmatrelvir/ritonavir (Paxlovid) | Oral antiviral for a new COVID-19 infection. | Limited Use 673, 674, 675 Positive test, symptoms for 5 days or less, and age 65+, immunocompromised, or 18 to 64 with a risk factor. |
| Remdesivir (Veklury) | IV antiviral for a new infection. CAN-PCC ranks it after Paxlovid. | Limited Use 722 High-risk patients who can’t take Paxlovid, started within 7 days of symptoms. With a prescriber’s referral, infusions are available in the community through Ontario Health atHome, mostly at nursing clinics and sometimes at home. |
| Molnupiravir (Lagevrio) | Oral antiviral for a new infection. CAN-PCC ranks it third. | Not listed Not authorized for use in Canada. |
| Antihistamines | For adults with signs and symptoms that fit mast cell activation syndrome (MCAS). | Depends on the product Cetirizine isn’t paid. Famotidine tablets (an H2 blocker) are General Benefits. |
| Melatonin | For adults with sleep problems, alongside sleep habit advice. | Not listed |
| Synbiotics or probiotics | For children and teens with Long COVID. | Not listed The Exceptional Access Program doesn’t fund natural health products. |
3. Prescribed in practice, paid out of pocket
There’s no approved treatment for Long COVID. Doctors work by careful trial and error, and many patients find relief from medications that haven’t yet been proven in large trials. Long COVID varies widely from person to person, so a drug that helps one group can look ineffective when trials study everyone together. When a doctor judges a medication worth trying for a disabling illness, cost shouldn’t decide whether a patient can try it.
| Drug | Prescribed for in Long COVID | Ontario Drug Benefit status | Research so far |
| Low-dose naltrexone (LDN) | Fatigue, pain, brain fog | Depends on the product Naltrexone 50 mg tablets are a General Benefit. Low doses (usually 1.5 to 4.5 mg) are made up by a compounding pharmacy; coverage of the compounded product isn’t confirmed. | CAN-PCC currently suggests against routine use, based on limited evidence; many clinicians and patients report benefit. CAN-PCC will re-evaluate this in 2026 (CAN-PCC). A Canadian placebo-controlled trial has finished; results aren’t posted yet (trial). |
| Rapamycin (sirolimus) | Immune and inflammation-related symptoms | Limited Use 392 Kidney transplant only. | Placebo-controlled trial underway, results expected after December 2026 (trial). |
| Tirzepatide (Mounjaro, Zepbound) | Fatigue, inflammation, brain fog | Not listed | Large placebo-controlled trial underway (trial). |
| Ketotifen | Mast cell symptoms (MCAS) | Not listed Tablets. | Small studies of antihistamines in Long COVID (study). |
| Guanfacine | Brain fog, attention | Limited Use 540 ADHD in ages 6 to 17 only. | Small study with N-acetylcysteine (NAC) (study). |
| Nicotine patches (NRT) | Fatigue, smell and taste changes | Not listed | Case reports (report). |
4. Supplements people commonly use
Supplements aren’t covered by Ontario’s drug plans, and the Exceptional Access Program doesn’t fund natural health products. The UK’s NICE guideline notes that it is “not known if over-the-counter vitamins and supplements are helpful, harmful or have no effect” in Long COVID (NICE). Many patients still find some of these help. Check with your pharmacist or prescriber, especially if you take other medications.
| Supplement | Commonly used for | Guidelines and research so far |
| Melatonin | Sleep | CAN-PCC suggests it for adults with sleep problems, alongside sleep habit advice (CAN-PCC). |
| Synbiotics or probiotics | Gut symptoms, fatigue | CAN-PCC suggests them for children and teens (CAN-PCC). In a Hong Kong trial in adults, a synbiotic improved fatigue and gut symptoms compared with placebo (study). |
| Electrolytes and extra salt and fluids | POTS: dizziness and fast heart rate on standing | Canada’s cardiology society advises increasing fluids and salt for POTS (CCS position statement). Check with a clinician first if you have high blood pressure, heart failure or kidney disease. |
| Magnesium | Fatigue, muscle cramps, sleep | Widely used. Research in Long COVID is limited; a trial in Mexico has finished but hasn’t posted results (trial). |
| Coenzyme Q10 | Fatigue | Widely used. A Danish trial found no overall benefit (study). |
This isn’t medical advice. Talk to your prescriber about whether any of these suit you. For an individual patient, a doctor or nurse practitioner can apply to the Exceptional Access Program, but it only considers a drug or use that Ontario’s Executive Officer has already approved for funding.
Evidence Ontario should weigh
Canada’s guideline
CAN-PCC suggests ivabradine, beta-blockers, pyridostigmine or midodrine as appropriate for post-COVID POTS or IST. The recommendation is conditional, with low certainty evidence.
Germany pays for it
Since 11 June 2026, German public insurance covers off-label ivabradine for post-COVID POTS when beta-blockers aren’t tolerated or suitable.
A new U.S. trial
In RECOVER-AUTONOMIC (181 adults), ivabradine lowered heart rate but didn’t significantly improve POTS symptoms overall. The full paper isn’t published yet.
The evidence is mixed. That’s why we’re asking for a formal review of who might benefit, not blanket coverage.
How you can help
Two short actions. Letters show health ministers that patients are waiting. Coverage reports show us where the gaps are, province by province.
Sources
Ontario coverage was checked against the Ontario Drug Benefit Formulary (effective 30 October 2026) on 8 November 2026. Sources checked 8 November 2026.